Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches
Yuefei Jin, Wangquan Ji, Haiyan Yang, Shuaiyin Chen, Weiguo Zhang, Guangcai Duan
Read Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches by Yuefei Jin, Wangquan Ji, Haiyan Yang, Shuaiyin Chen, Weiguo Zhang, Guangcai Duan in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7758411.txt.
Introduction
Jin and co-authors review how COVID-19 activates and damages the lining of blood vessels. Endothelial cells line all vessels and carry high levels of the viral entry protein ACE2. They govern inflammation and clotting at the vessel wall. Evidence ties their dysfunction to severe disease.
When these cells switch on, the vessel barrier leaks and clots form more readily. Inflammation at the wall grows, and white blood cells slip into tissue. Lung vessel damage is a hallmark of the acute respiratory failure that kills patients. The authors set out the cell and molecular steps in this process. They end with treatments that aim to protect the vessel lining.
Catalog record
| CREATOR | Yuefei Jin, Wangquan Ji, Haiyan Yang, Shuaiyin Chen, Weiguo Zhang, Guangcai Duan |
|---|---|
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches By Yuefei Jin, Wangquan Ji, Haiyan Yang, Shuaiyin Chen, Weiguo Zhang, Guangcai Duan Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-020-00454-7 ABSTRACT On 12 March 2020, the outbreak of coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. As of 4 August 2020, more than 18 million confirmed infections had been reported globally. Most patients have mild symptoms, but some patients develop respiratory failure which is the leading cause of death among COVID-19 patients. Endothelial cells with high levels of angiotensin-converting enzyme 2 expression are major participants and regulators of inflammatory reactions and coagulation. Accumulating evidence suggests that endothelial activation and dysfunction participate in COVID-19 pathogenesis by altering the integrity of vessel barrier, promoting pro-coagulative state, inducing endothelial inflammation, and even mediating leukocyte infiltration. This review describes the proposed cellular and molecular mechanisms of endothelial activation and dysfunction during COVID-19 emphasizing the principal mediators and therapeutic implications. INTRODUCTION In late 2019, an emerging viral pneumonia caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), termed coronavirus disease 2019 (COVID-19), was first reported in Wuhan, Hubei Province, China.1,2 This disease has infected more than 18 million people and lead to more than 500,000 deaths worldwide.3 In general, COVID-19 is considered self-limited, and many of those infected have mild symptoms or appear to be asymptomatic; however, some patients develop respiratory failure which is the leading cause of death among infections with COVID-19.4–6 To date, no specific drugs and vaccines are yet available for COVID-19, and its pathogenesis remains largely unclear. Endothelial cells (ECs) mostly exist in the inner layer of all blood vessels and are normally protected by pericytes.7 Pulmonary ECs function as the basic barrier between blood and interstitium, accounting for one-third of cells in the lung.8,9 The activation and dysfunction of pulmonary ECs are considered signs of ARDS and the primary pathological causes.10,11 Accumulating evidence indicates that SARS-CoV-2 infection exerts adverse effects on the endothelium of capillary, which may contribute to COVID-19 pathogenesis by altering the integrity of vessel barrier, promoting pro-coagulative state, inducing endothelial inflammation, and even mediating leukocyte infiltration.12,13 Patients with severe or critical COVID-19 admitted in intensive care units frequently present underlying conditions (old age, diabetes, hypertension, and cardiovascular diseases).5 These comorbidities are often accompanied by years of chronic endothelial dysfunction.13,14 Endothelial activation and dysfunction are suggested to be related to the coagulation cascade.15 Established evidence suggests that activation of the coagulation pathway with the possible development of disseminated intravascular coagulation (DIC) is a feature of severe COVID-1916,17 that may further result in thrombus formation.18 Therefore, it was suggested to name severe pulmonary COVID-19 as the microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome or MicroCLOTS.19 To date, the ongoing global pandemic of COVID-19 still poses a considerable threat to many people.20 An improved mechanistic understanding of endothelial activation and dysfunction is of utmost importance. This review describes the possible cellular and molecular mechanisms of endothelial activation and dysfunction in COVID-19, emphasizing the principal mediators and the therapeutic implications. PATHOPHYSIOLOGY OF ECS The primary histological characteristic of resting ECs is their cobblestone shape; however, they constitute more than static mechano-protective plates (Fig. 1).21 ECs mostly exist in the inner layer of blood vessels and are normally protected by pericytes that support the vessel structure.7 ECs have different functions and structures depending on the tissues and organs. For example, pulmonary vascular ECs are arranged in a dense monolayer, forming a protective barrier that is in direct contact with blood components.9 The commonly accepted functions of ECs in the homeostasis of body physiology are controlling vascular permeability and regulating vascular tone (Fig. 1).21 ECs can synthesize and release various endothelium-derived relaxation factors, such as nitric oxide (NO) and prostaglandin (PG), and contractile factors, including endothelin (ET), thromboxane A2 (TXA2), reactive oxygen species (ROS), and angiotensin II (Ang II), which play significant roles in the regulation of vascular tone (Fig. 1).22 When activated, ECs secrete chemoattractants, cytokines, and adhesion molecules, leading to augmented blood vessel permeability (Fig. 1).21 In resting ECs, the synthesis of these molecules can be suppressed by NO.23 In addition, ECs are also involved in adhesion and aggregation of platelets, activation, adhesion, and migration of leukocytes, and fibrin balance (Fig. 1).24 NO exerts direct effects on leukocytes, preventing their activation into motile forms that are capable of entering tissues.23 However, dysfunctional endothelial response to damage or infection cannot produce sufficient amounts of NO.23 Therefore, a decline in NO bioavailability always represents endothelial dysfunction.Fig. 1Pathophysiology of endothelial cells. Endothelial cells exist in the inner layer of blood vessels (a) such as arteries (b), veins (c), and capillaries (d), and are normally protected by pericytes that support the vessel structure. Tight junctions link neighboring cells and help maintain tissue integrity, act as barriers to permeability. The regulation of vascular tone, and permeability upon activation are illustrated ENDOTHELIAL ACTIVATION AND DYSFUNCTION ARE ASSOCIATED WITH COVID-19 SEVERITY Epidemiological studies suggest that severe cases or deaths due to COVID-19 frequently present with underlying comorbidities, such as advanced age, hypertension, diabetes, and cardiovascular diseases.5 Chronic vascular endothelial injury often co-occurs in patients with such comorbidities.14 Most patients with critical COVID-19 die from ARDS, pulmonary edema, cytokine storm, multiple organ failure, and diffuse coagulopathy.4 Among the aforementioned causes, ARDS has been considered a result of pulmonary EC damage.12 The direct or indirect activation of ECs mediates the extensive production of inflammatory cytokines, adhesion molecules, and chemokines, which may result in cytokine storm, local inflammatory cell infiltration, and vascular leakage.12,21,23 The plasma levels of adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-1), fractalkine, vascular cell adhesion molecule-1 (VCAM-1), vascular adhesion protein-1 (VAP-1), and vascular endothelial growth factor (VEGF), had been reported to be elevated among COVID-19 patients, especially in severe patients.25,26 Clinical findings also indicate an increased occurrence of Kawasaki disease, a form of vasculitis, in pediatric patients with COVID-19, implying acute vascular inflammation.27,28 The dysfunction of ECs fails to release sufficient amounts of NO, resulting in vessel constriction.23 NO deficiency has been observed among COVID-19 patients,29 and it may cause vascular smooth muscle contraction, reducing the ability to neutralize ROS and NO-mediated antiviral capability.30,31 ECs function as key regulators of coagulation and as counterbalance for thrombin.32 A dysfunctional endothelial response to viral infection can activate the coagulation pathway and lead to anticoagulation imbalance.7 Comprehensive coagulation analyzes of patients with COVID-19 indicate elevated levels of D-dimer, increased fibrinogen, enhanced platelet activation, and increased variables of viscoelastic in the plasma of severe cases.33,34 Elevated D-dimer levels in critical patients represent poor prognosis.35 In addition to venous thromboembolism, the association of microthrombus formation with multiple organ failure and acro-ischemic change has been proposed.36 The pathological manifestations leading to severe COVID-19 have been recently considered as vascular leakage, inflammatory reactions, anticoagulation imbalance, and endothelial dysfunction, which may play a central role in the aforementioned procedure.12 Therefore, understanding the mechanisms of endothelial activation and dysfunction during the course of COVID-19 infection will help in the early identification of individuals which are at risk of suffering from severe complications, and thus, provide appropriate therapeutic targets. The overview of endothelial activation and dysfunction in COVID-19 pathogenesis is shown in Fig. 2.Fig.